IL23A and triple-A syndrome: Although a previous study finds that genetic disruption of IL-23 attenuated elastase-induced AAA23, our key finding herein is that therapeutic blockade of the IL-12/IL-23 axis effectively suppresses AAA progression when given in the early phase of aneurysm development.